Switzerland· 59390002
Onglyza 2.5 mg, Filmtabletten
A saxagliptin product containing saxagliptinum, registered in Switzerland by AstraZeneca AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Saxagliptin is registered in 16 of 19 countries.
Countries holding a registration under ATC A10BH03 (saxagliptin), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 10 of them publish a price we can compare per daily dose
Saxagliptin · ATC A10BH03
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of saxagliptin costs, country by country.
Normalised to the WHO defined daily dose (5 mg), the median price runs from $0.31 in France to $3.59 in Italy — a ×12 gap.
- Switzerland: $3.41 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Saxagliptin · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- IT Italy$3.59
- CH Switzerland$3.41
- FR France$0.31
The record
At a glance
Swissmedic (Switzerland)- Active substance
- saxagliptinum
- Manufacturer
- AstraZeneca AG
- Country
- Switzerland (CH)
- ATC code
- A10BH03
- ATC class
- Saxagliptin
- Defined daily dose
- 5 mg, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin768059390002998 StkCHF 116.85
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
449 interactions on record for saxagliptin.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Saxagliptin · interactions on record
449 records
- 3 severe
- 404 moderate
- 42 minor
Most severe, free to view
- ClotrimazoleA01AB18moderate
- CimetidineA02BA01moderate
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Saxagliptin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomOnglyza 2.5mg tabletsMawdsley-Brooks & Company Ltd
- CanadaAPO-SAXAGLIPTINAPOTEX INC
- CzechiaONGLYZAAstraZeneca AB, Södertälje
- United StatesSaxagliptinAurobindo Pharma Limited
- BelgiumOnglyza 2.5 mgAstraZeneca
- NetherlandsOnglyza 2,5 mg, filmomhulde tablettenAstraZeneca AB
- SpainONGLYZA 2,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- FranceONGLYZA 5 mg, comprimé pelliculéASTRAZENECA AB
Authorised across Europe · EMA
The same active substance is authorised in 9 EEA countries. Names it is sold under:
- France · Saxagliptine Arrow, Saxagliptine Biogaran
- United Kingdom (Northern Ireland) · Saxagliptin Sandoz, Saxagliptin Zydus Pharmaceuticals Uk
- Hungary · Saxagliptin Pharos
- Iceland · Onglyza
- Liechtenstein · Onglyza
- Malta · Saxagliptin Pharos
- Netherlands · Saxagliptine Sandoz
- Norway · Onglyza
- Portugal · Saxagliptina Generis, Saxagliptina Generis Phar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d0eb6bef-b109-493f-9c10-3bfca18d4eaa GET /v1/drugs/d0eb6bef-b109-493f-9c10-3bfca18d4eaa?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "saxagliptinum 2.5 mg",
"valid_from": "2010-03-01",
"limitations": "[{\"description\":\"Zur Behandlung von Patienten mit einem Typ 2 Diabetes mellitus, wenn mit Diät und vermehrter körperlicher Aktivität keine ausreichende Kontrolle der Glykämie erreicht wird:<br>\\n- Als Monotherapie, für Patienten, welche mit den bisherigen oralen Therapien nur ungenügend eingestellt werden können oder diese nicht vertragen.<br>\\n- Als Zweifachkombination mit<br>\\n - Metformin oder<br>\\n - mit einem Sulfonylharnstoff oder<br>\\n - mit einem Thiazolidindion, wenn mit diesen Behandlungen keine ausreichende Kontrolle der Glykämie erreicht werden kann.<br>\\n- Als Dreifachkombination mit Metformin und einem Sulfonylharnstoff, wenn mit Metformin und einem Sulfonylharnstoff (als Zweifachkombination und maximal verträglicher Dosierung) zusammen mit Diät und vermehrter körperlicher Aktivität keine ausreichende Kontrolle der Glykämie erreicht wird.<br>\\n- In Kombination mit Insulin (mit oder ohne Metformin), wenn durch diese Massnahmen keine ausreichende Kontrolle der Glykämie erreicht werden kann.<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2023-12-01\"}]",
"galenic_form": "Tabl 2.5 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2010-03-01",
"self_retention_pct": 10
}See everything about saxagliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.